FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067579866> ?p ?o ?g. }

• W2067579866 endingPage "834" @default.
• W2067579866 startingPage "830" @default.
• W2067579866 abstract "Octreotide, a long-acting somatostatin analogue, has demonstrated clinical utility in patients with carcinoid syndrome and malignant islet cell tumors of the pancreas. Prior studies have reported a greater than expected incidence of cholelithiasis in patients treated with octreotide for acromegaly. This study attempted to determine the incidence and morbidity of cholelithiasis in a group of patients with metastatic carcinoid or malignant pancreatic islet cell tumors who were receiving chronic therapy with octreotide.Forty-four of 55 patients on investigational protocols with octreotide were eligible for chart review; 10 patients were excluded due to prior cholecystectomy and 1 patient due to asymptomatic cholelithiasis at presentation. Patients fell into three treatment groups. The low dose (LD) group was comprised of 17 patients receiving 150 microg of subcutaneous octreotide 3 times a day. Twenty-one patients received high dose (HD) therapy comprised of 500 microg given 3 times a day. The low dose-high dose (LD-HD) group was comprised of 6 patients who had their dose escalated from 150 microg to 225-500 microg of octreotide 3 times a day.The overall incidence of cholelithiasis and/or gallbladder sludge was found to be 52.3% in all 3 treatment groups. Three of the 44 patients (6.8%) had symptomatic disease requiring emergency cholecystectomy. Five other patients underwent elective or incidental gallbladder surgery. The incidence of cholelithiasis in the LD, LD-HD, and HD groups was 35.3%, 66.6%, and 61.9%, respectively. The incidence of acute cholecystitis in the three groups was 11.8%, 0%, and 4.8%, respectively.Although greater than 50% of patients receiving octreotide developed cholelithiasis, a much smaller percentage of patients had symptomatic gallbladder disease. Patients receiving chronic octreotide treatment require monitoring for the development of gallstones. However, prophylactic cholecystectomy is not indicated, unless it is performed in conjunction with bowel resection or cytoreductive hepatic surgery." @default.
• W2067579866 created "2016-06-24" @default.
• W2067579866 creator A5012529799 @default.
• W2067579866 creator A5069775640 @default.
• W2067579866 creator A5089225736 @default.
• W2067579866 date "1997-02-15" @default.
• W2067579866 modified "2023-09-24" @default.
• W2067579866 title "Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors" @default.
• W2067579866 cites W1499345514 @default.
• W2067579866 cites W1970252755 @default.
• W2067579866 cites W1974172715 @default.
• W2067579866 cites W1975789485 @default.
• W2067579866 cites W1980031502 @default.
• W2067579866 cites W1989883614 @default.
• W2067579866 cites W1993864967 @default.
• W2067579866 cites W1998933514 @default.
• W2067579866 cites W2004700740 @default.
• W2067579866 cites W2012615488 @default.
• W2067579866 cites W2015058101 @default.
• W2067579866 cites W2015521569 @default.
• W2067579866 cites W2019844114 @default.
• W2067579866 cites W2036303399 @default.
• W2067579866 cites W2036876214 @default.
• W2067579866 cites W2043222014 @default.
• W2067579866 cites W2052659096 @default.
• W2067579866 cites W2062369552 @default.
• W2067579866 cites W2063488172 @default.
• W2067579866 cites W2068217221 @default.
• W2067579866 cites W2069087191 @default.
• W2067579866 cites W2075859363 @default.
• W2067579866 cites W2085380131 @default.
• W2067579866 cites W2108714534 @default.
• W2067579866 cites W2155814702 @default.
• W2067579866 cites W2317423322 @default.
• W2067579866 cites W2337135362 @default.
• W2067579866 doi "https://doi.org/10.1002/(sici)1097-0142(19970215)79:4<830::aid-cncr20>3.0.co;2-#" @default.
• W2067579866 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9024721" @default.
• W2067579866 hasPublicationYear "1997" @default.
• W2067579866 type Work @default.
• W2067579866 sameAs 2067579866 @default.
• W2067579866 citedByCount "36" @default.
• W2067579866 countsByYear W20675798662012 @default.
• W2067579866 countsByYear W20675798662013 @default.
• W2067579866 countsByYear W20675798662014 @default.
• W2067579866 countsByYear W20675798662015 @default.
• W2067579866 countsByYear W20675798662016 @default.
• W2067579866 countsByYear W20675798662017 @default.
• W2067579866 countsByYear W20675798662018 @default.
• W2067579866 countsByYear W20675798662019 @default.
• W2067579866 countsByYear W20675798662020 @default.
• W2067579866 countsByYear W20675798662022 @default.
• W2067579866 countsByYear W20675798662023 @default.
• W2067579866 crossrefType "journal-article" @default.
• W2067579866 hasAuthorship W2067579866A5012529799 @default.
• W2067579866 hasAuthorship W2067579866A5069775640 @default.
• W2067579866 hasAuthorship W2067579866A5089225736 @default.
• W2067579866 hasConcept C120665830 @default.
• W2067579866 hasConcept C121332964 @default.
• W2067579866 hasConcept C126322002 @default.
• W2067579866 hasConcept C141071460 @default.
• W2067579866 hasConcept C2775967933 @default.
• W2067579866 hasConcept C2776297358 @default.
• W2067579866 hasConcept C2776641081 @default.
• W2067579866 hasConcept C2777433750 @default.
• W2067579866 hasConcept C2777910003 @default.
• W2067579866 hasConcept C2779066768 @default.
• W2067579866 hasConcept C2781025020 @default.
• W2067579866 hasConcept C2984496839 @default.
• W2067579866 hasConcept C61511704 @default.
• W2067579866 hasConcept C71315377 @default.
• W2067579866 hasConcept C71924100 @default.
• W2067579866 hasConcept C90924648 @default.
• W2067579866 hasConceptScore W2067579866C120665830 @default.
• W2067579866 hasConceptScore W2067579866C121332964 @default.
• W2067579866 hasConceptScore W2067579866C126322002 @default.
• W2067579866 hasConceptScore W2067579866C141071460 @default.
• W2067579866 hasConceptScore W2067579866C2775967933 @default.
• W2067579866 hasConceptScore W2067579866C2776297358 @default.
• W2067579866 hasConceptScore W2067579866C2776641081 @default.
• W2067579866 hasConceptScore W2067579866C2777433750 @default.
• W2067579866 hasConceptScore W2067579866C2777910003 @default.
• W2067579866 hasConceptScore W2067579866C2779066768 @default.
• W2067579866 hasConceptScore W2067579866C2781025020 @default.
• W2067579866 hasConceptScore W2067579866C2984496839 @default.
• W2067579866 hasConceptScore W2067579866C61511704 @default.
• W2067579866 hasConceptScore W2067579866C71315377 @default.
• W2067579866 hasConceptScore W2067579866C71924100 @default.
• W2067579866 hasConceptScore W2067579866C90924648 @default.
• W2067579866 hasIssue "4" @default.
• W2067579866 hasLocation W20675798661 @default.
• W2067579866 hasLocation W20675798662 @default.
• W2067579866 hasOpenAccess W2067579866 @default.
• W2067579866 hasPrimaryLocation W20675798661 @default.
• W2067579866 hasRelatedWork W1980179575 @default.
• W2067579866 hasRelatedWork W2004517907 @default.
• W2067579866 hasRelatedWork W2007123753 @default.
• W2067579866 hasRelatedWork W2083064369 @default.
• W2067579866 hasRelatedWork W2105705536 @default.

• next